Amraie Mehrjoo, Khorraminejad-Shirazi Mohammadhossein, Nabavizadeh Ali, Mokhtari Maral
Department of Pathology, School of Medicine, Shiraz University of Medical Sciences.
Student research committee, Shiraz University of Medical Sciences.
Appl Immunohistochem Mol Morphol. 2025 Jul 1;33(4):257-263. doi: 10.1097/PAI.0000000000001265. Epub 2025 May 22.
Determining the origin of mucinous adenocarcinomas can be challenging due to overlapping histologic and immunohistochemical features. This study evaluates the utility of SATB2 and villin immunohistochemical markers for defining mucinous adenocarcinomas' origin. We retrospectively analyzed 71 patients with mucinous adenocarcinomas-31 lower gastrointestinal (GI), 28 ovarian, and 12 cases of pseudomyxoma peritonei. Immunohistochemistry for SATB2 and villin was performed on ovarian and GI tumor samples. Sensitivity, specificity, and positive and negative predictive values were calculated to assess diagnostic performance.For identifying GI origin, SATB2 showed 87.1% sensitivity and 100% specificity, while villin exhibited 93.5% sensitivity but only 21.4% specificity. Dual SATB2/villin positivity demonstrated 80.6% sensitivity and 100% specificity for GI origin. For ovarian origin, dual SATB2/villin negativity provided 100% specificity. Logistic regression analysis on the adenocarcinoma cases showed 93.2% accuracy rate of dual staining with SATB2 and villin for predicting GI versus ovarian origin. SATB2 exhibits high specificity for GI mucinous adenocarcinomas, and villin is highly sensitive. Combining SATB2 and villin optimizes diagnostic performance for differentiating the primary origin site of mucinous adenocarcinomas and determining pseudomyxoma peritonei origin. Moreover, the presence of signet ring morphology prompted reconsideration of possible GI origin among our cases. A multimarker immunohistochemical panel, including SATB2 and villin can enhance the diagnostic accuracy of challenging mucinous adenocarcinoma cases.
由于组织学和免疫组化特征重叠,确定黏液腺癌的起源可能具有挑战性。本研究评估SATB2和绒毛蛋白免疫组化标志物在确定黏液腺癌起源方面的效用。我们回顾性分析了71例黏液腺癌患者——31例下消化道(GI)癌、28例卵巢癌和12例腹膜假黏液瘤。对卵巢和GI肿瘤样本进行了SATB2和绒毛蛋白的免疫组化检测。计算敏感性、特异性以及阳性和阴性预测值以评估诊断性能。为了确定GI起源,SATB2的敏感性为87.1%,特异性为100%,而绒毛蛋白的敏感性为93.5%,但特异性仅为21.4%。SATB2/绒毛蛋白双阳性对GI起源的敏感性为80.6%,特异性为100%。对于卵巢起源,SATB2/绒毛蛋白双阴性的特异性为100%。对腺癌病例进行的逻辑回归分析显示,SATB2和绒毛蛋白双重染色预测GI与卵巢起源的准确率为93.2%。SATB2对GI黏液腺癌具有高特异性,而绒毛蛋白具有高敏感性。联合使用SATB2和绒毛蛋白可优化诊断性能,以区分黏液腺癌的原发起源部位并确定腹膜假黏液瘤的起源。此外,印戒形态的存在促使我们重新考虑病例中可能的GI起源。包括SATB2和绒毛蛋白在内的多标志物免疫组化组合可提高疑难黏液腺癌病例的诊断准确性。